Safety and efficacy analysis of HIV and HBV/HCV cohorts
| Cohorts (N) | ORRaN (%) | Any Grade irAEsN (%) | Grade ≥ 3 irAEsN (%) |
|---|---|---|---|
| HIV (21) | 2 CR/3 PR (28) | 5 (24) | 3 (14) |
| HBV/HCV (34) | 6 PR (18) | 15 (44) | 10 (29)b |
aResponse evaluable patients HIV: 18; HBV/HCV: 34, b Two patients with baseline grade ≥ 2 hepatitis